3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
44
Uveal Melanoma
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hodgkin Disease
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large-Cell, Immunoblastic
5
Burkitt Lymphoma
5
Sezary Syndrome
4
Neoplasm Metastasis
4
Myelodysplastic Syndromes
4
Mycosis Fungoides
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Acute
4
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Waldenstrom Macroglobulinemia
3
Recurrence
3
Primary Myelofibrosis
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lung Neoplasms
3
Interventions
pembrolizumab
27
Nivolumab
20
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
avelumab
3
Pemetrexed
3
Interleukin-2
3
tislelizumab
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Cisplatin
2
veliparib
1
toripalimab
1
spartalizumab
1
sotigalimab
1
sonidegib
1
sargramostim
1
regorafenib
1
poly ICLC
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
sargramostim
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled